Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Immunol. Jul 24, 2021; 11(1): 1-10
Published online Jul 24, 2021. doi: 10.5411/wji.v11.i1.1
New era of personalized medicine: Advanced therapy medicinal products in Europe
Javier García-González, Sonia Marhuenda-Castillo, Sheila Romero-Carretero, Jesús Beltrán-García
Javier García-González, Strategy and Market Access, Pharmaceutical Industry, Madrid 28012, Spain
Sonia Marhuenda-Castillo, Sheila Romero-Carretero, Clinical Research, International CRO, Madrid 28003, Spain
Jesús Beltrán-García, Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia 46010, Spain
Jesús Beltrán-García, Center for Biomedical Research in Rare Diseases Network (CIBERER), Carlos III Health Institute, Valencia 46010, Spain
Jesús Beltrán-García, INCLIVA Institute of Sanitary Research, Valencia 46010, Spain
Author contributions: García-González J wrote the original draft; Marhuenda-Castillo S and Romero-Carretero S contributed to the original draft writing and prepared the summarized table; Beltrán-García J conceptualized, established, and directed the draft execution.
Conflict-of-interest statement: The authors have no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Jesús Beltrán-García, PhD, Academic Research, Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Av. de Blasco Ibáñez, 15, Valencia 46010, Spain.
Received: January 14, 2021
Peer-review started: January 14, 2021
First decision: February 15, 2021
Revised: February 24, 2021
Accepted: June 7, 2021
Article in press: June 7, 2021
Published online: July 24, 2021
Core Tip

Core Tip: The advanced therapy medicinal products (ATMPs) have opened a new world of possibilities in the prevention and treatment of a large number of diseases that have not been effectively treated to date. ATMPs are based on the use of novel and sophisticated technologies adapted to each patient (personalized medicine), as well as on the discovery of novel and reliable biomarkers for the prediction and monitoring of clinical response. In this work we describe the latest advances in ATMPs approved by the European Medicines Agency, the molecular mechanisms that guided their medical benefits, how they work, the current status, and how they can change the medicine field forever, approaching precision personalized medicine.